| Code | CSB-RA004847MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Azirkitug, targeting C-C chemokine receptor type 8 (CCR8), a G protein-coupled receptor predominantly expressed on regulatory T cells (Tregs) and certain T helper cell subsets. CCR8 mediates chemotaxis in response to its ligands CCL1 and CCL18, playing a crucial role in immune cell trafficking and localization within tissues, particularly in tumor microenvironments. Elevated CCR8 expression on intratumoral Tregs has been associated with immune suppression in various cancers, making it an attractive target for cancer immunotherapy research.
Azirkitug represents a therapeutic antibody designed to selectively deplete CCR8-positive regulatory T cells within tumors while preserving peripheral immune function. This biosimilar provides researchers with a valuable tool for investigating CCR8-mediated immunoregulatory mechanisms, studying Treg biology in cancer and inflammatory conditions, and exploring novel immunotherapeutic strategies. The antibody is particularly useful for preclinical studies examining tumor immunity, immune checkpoint modulation, and the role of tissue-resident Tregs in disease pathogenesis.
There are currently no reviews for this product.